Pharmaceutical giant Pfizer (NYSE: PFE) on Tuesday released its first-quarter 2022 earnings report, with solid results on the revenue and earnings per share lines that beat market forecasts. The covid-19 vaccine alone generated revenue of US$ 13.5 billion (R$ 67 billion), more than half of all the company’s sales in the period.
Below is a comment by Rafael Bevilacqua, chief strategist and founding partner of the analysis house Levante Ideias de Investimento, on the subject. Every day, Bevilacqua brings news and reviews of publicly traded companies for you to make the best investment decisions. This content is accessible to subscribers to UOL. O UOL has an exclusive area for those who want to invest their money safely and profit more than with savings. Meet!
Driven by high demand for vaccines against Covid-19, the company’s sales totaled US$ 25.6 billion in the quarter, which corresponds to a growth of 77% compared to the same period of the previous year. The coronavirus immunizer totaled $13.2 billion in sales – more than half of the total volume.
The company’s net income was US$7.8 billion in the period, 61% higher than in the first quarter of 2021. Adjusted earnings per share were US$1.62, above expectations.
In addition to reporting strong results, the drugmaker released its goals for this year, which include sales volume of between $98 billion and $102 billion, and earnings per share of between $6.25 and $6.45.
The earnings forecast previously ranged from $6.35 to $6.55 per share, but was lowered as R&D is expected to rise, especially those related to the Covid-19 vaccine.
In short, the results came out solid and encouraging, while the projections brought ambiguous data. In this context, I believe that stocks should react with contained fluctuations in the short term, since the balance sheet was mostly in line with market expectations.
On Tuesday (3), Pfizer shares closed up 1.97%, quoted at US$ 49.29.